Harnessing a T1 Phage-Derived Spanin for Developing Phage-Based Antimicrobial Development

• Published in: Biodesign research 2024, Vol.6, p.0028-0028
• Main Authors: Yamashita, Wakana, Ojima, Shinjiro, Tamura, Azumi, Azam, Aa Haeruman, Kondo, Kohei, Yuancheng, Zhang, Cui, Longzhu, Shintani, Masaki, Suzuki, Masato, Takahashi, Yoshimasa, Watashi, Koichi, Tsuneda, Satoshi, Kiga, Kotaro
• Format: Article
• Language: English
• ISSN: 2693-1257; 2693-1257
• DOI: 10.34133/bdr.0028

The global increase in the prevalence of drug-resistant bacteria has necessitated the development of alternative treatments that do not rely on conventional antimicrobial agents. Using bacteriophage-derived lytic enzymes in antibacterial therapy shows promise; however, a thorough comparison and evaluation of their bactericidal efficacy are lacking. This study aimed to compare and investigate the bactericidal activity and spectrum of such lytic enzymes, with the goal of harnessing them for antibacterial therapy. First, we examined the bactericidal activity of spanins, endolysins, and holins derived from 2 model phages, T1 and T7. Among these, T1-spanin exhibited the highest bactericidal activity against Subsequently, we expressed T1-spanin within bacterial cells and assessed its bactericidal activity. T1-spanin showed potent bactericidal activity against all clinical isolates tested, including bacterial strains of 111 , 2 spp., 3 spp., and 3 . In contrast, T1 phage-derived endolysin showed bactericidal activity against and , yet its efficacy against other bacteria was inferior to that of T1-spanin. Finally, we developed a phage-based technology to introduce the T1-spanin gene into target bacteria. The synthesized non-proliferative phage exhibited strong antibacterial activity against the targeted bacteria. The potent bactericidal activity exhibited by spanins, combined with the novel phage synthetic technology, holds promise for the development of innovative antimicrobial agents.